GlobeNewswire

Novartis announces change to the Executive Committee

Share
  • Shannon Klinger, Chief Legal Officer, to leave Novartis on March 15, 2021

  • Thomas Kendris appointed Chief Legal Officer ad interim

Basel, March 5, 2021 — Novartis announced today that Shannon Thyme Klinger, Chief Legal Officer, has decided to resign from Novartis and return to the US to take an executive role at a biotechnology company. Ms. Klinger will step down from the Executive Committee of Novartis (ECN), effective March 15, 2021.

Thomas N. Kendris, currently Global Head Litigation and US Country President, will be appointed Chief Legal Officer ad interim and attendee to the ECN in this capacity. Novartis has started an executive search process to evaluate internal and external candidates for the role of its Chief Legal Officer.

As Global Head of Litigation, Mr. Kendris has been accountable for leading Novartis Group material litigations and investigations globally. In his more than 25 years with Novartis, he was Novartis US Country Head of Legal, and held country-level responsibility for Legal across all Novartis US Divisions. He also served as Vice President and General Counsel of US Pharma at Novartis Pharmaceuticals Corporation, as well as Global General Counsel for Novartis Oncology and for Novartis Vaccines and Diagnostics.

Vas Narasimhan, CEO of Novartis said: “I thank Shannon for her leadership, counsel, and impact on our businesses over 10 years with our company. She has created one of the most respected legal departments within the industry, including for its commitment to diversity and inclusion. I wish her the very best for her future. We are pleased that Tom Kendris, with his 25 years of experience across Novartis businesses, will serve ad-interim as Chief Legal Officer.”

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “to leave,” “ad interim,” “started,” “potential,” “will,” “may,” “could,” “would,” “expect,” “wish,” “commitment,” or similar terms, or by express or implied discussions regarding the appointment of Mr. Kendris as Chief Legal Officer ad interim and attendee to the ECN in this capacity, and regarding the executive search process to evaluate candidates for the role of Novartis Chief Legal Officer. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the executive search process to evaluate candidates for the role of Chief Legal Officer will achieve the desired outcome, or that it will do so in any particular time frame. In particular, our expectations regarding the outcome of the forward looking statements in this press release could be affected by, among other things, the availability of qualified and interested candidates for the role of Novartis Chief Legal Officer; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visithttps://www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com

# # #

Novartis Media Relations
E-mail: media.relations@novartis.com

Richard Jarvis
Novartis Strategy & Financial
Communications
+44 7966 118 652
richard.jarvis@novartis.com

Julie Masow
Novartis US External Engagement
+1 862 579 8456
julie.masow@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

CentralNorth America
Samir Shah+41 61 324 7944Sloan Simpson+1 862 778 5052
Thomas Hungerbuehler        
Isabella Zinck
+41 61 324 8425
+41 61 324 7188

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Interim Report January-March 202122.4.2021 18:30:00 CEST | Press release

First quarter 2021 Net profit for the first quarter amounted to MSEK 44.6 (-4.0).Earnings per share amounted to SEK 4.00 (-0.35).Net asset value amounted to MSEK 703 (SEK 63.04 per share) at March 31, 2021, compared to MSEK 679 (SEK 60.87 per share) at March 31, 2020.Net cash amounted to MSEK 180 (SEK 16.16 per share) at March 31, 2021, compared to MSEK 219 (SEK 19.65 per share) at December 31, 2020.The 2021 Annual General Meeting resolved to pay a dividend of 3.00 SEK per share for FY 2020. Comments by the CEO NAXS experienced a steady development during the first quarter of 2021 with the NAV/share increasing by 8.5%, including the dividend paid out. During the quarter, NAXS made a second co-investment alongside JAB Holding, this time in Krispy Kreme Doughnuts, the world-famous doughnut brand. As to the underlying funds, they acquired 4 new portfolio companies and signed or closed 4 exits during the quarter. In addition, a partial exit took place with the listing of Kreate on Nasdaq H

Prosafe SE: Supporting statement to the 2020 Annual Report in light of the ruling in the Westcon matter22.4.2021 18:30:00 CEST | Press release

Reference is made to Prosafe's annual accounts for 2020 published on 25 March 2021 as well as the notice for annual general meeting published on 12 April 2021. Reference is further made to announcement on 15 April 2021, in which Prosafe informed that the Gulating Court of Appeal had decided against Prosafe in the Westcon matter, thereby awarding full payment to Westcon of amounts claimed and thus reversing the ruling by the Stavanger District Court in the first instance. In light of the ruling, Prosafe has today issued a supporting statement to its 2020 annual report and accounts. The statement is attached. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com Stavanger, 22 April 2021 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24 30 / +47 907 65 155 Stig Harry Christiansen, Deputy CEO

Delårsrapport januari – mars 202122.4.2021 18:30:00 CEST | Pressemelding

Första kvartalet 2021 Resultat efter skatt uppgick till 44,6 (-4,0) MSEK.Resultatet per aktie uppgick till 4,00 (-0,35) SEK.Substansvärdet uppgick till 703 MSEK (63,04 SEK per aktie) per den 31 mars 2021, jämfört med 679 MSEK (SEK 60,87 per aktie) per den 31 december 2020. Nettokassan uppgick till 180 MSEK (16,16 SEK per aktie) per den 31 mars 2021, jämfört med 219 MSEK (19,65 SEK per aktie) per den 31 december 2020.Årsstämman 2021 beslutade att lämna en utdelning om 3,00 SEK per aktie. VD-kommentar NAXS utvecklades positivt under första kvartalet och substanvärdet per aktie ökade med 8,5% inklusive lämnad utdelning. Under första kvartalet gjorde NAXS ytterligare en saminvestering parallellt med JAB Holding, denna gång i Krispy Kreme Doughnuts verksamt i USA. Vad gäller underliggande fonder förvärvade dessa 4 nya portföljbolag och undertecknade eller genomförde 4 exit under perioden. Vidare genomfördes en partiell exit genom börsnotering av Kreate på Nasdaq Helsingfors. NAXS lämnade un

Conagen’s Novel Solution to Making Natural Capsaicin by Fermentation Accessible22.4.2021 18:23:30 CEST | Press release

Bedford, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Scalable, sustainable capsaicin ingredients for its use in food, consumer and industrial products have now become more accessible. Conagen announced it has successfully scaled-up its fermentation process for the production of premium capsaicin and its related capsaicinoid molecules. Chili peppers are widely used as a food additive in spicy and hot cuisines, due to its hot and pungent characteristics. Consumers globally are demanding more clean, natural and exciting flavors, especially hot and spicy flavors. Yet, the challenge in meeting this demand is that capsaicin from chili peppers is difficult to use because of its hot properties, proposing challenges to manufacturers. Capsaicin extraction is limited by the availability of chili peppers, which is subject to fluctuations in price and quality. The market for capsaicin is growing because of its pungent characteristic, which is very versatile in a broad spectrum of applications, includ

OREGE: Annual results 2020 and outlook22.4.2021 18:05:00 CEST | Press release

PRESS RELEASE Voisins Le Bretonneux, 22 April 2021 – 6 PM ANNUAL RESULTS 2020 AND OUTLOOK ___________________________________________________________________ Summary financial information for the year ended December 31 2020. Strong growth in turnover which validates the commercial approach taken by Orege in recent years 15% decrease in net operating expenses, thanks to savings on the Group's fixed costs. (Consolidated financial statements approved by the board of directors on 21 April 2021. The audit procedures by the statutory auditors are being finalized.) In k€ - IFRS2020 2019 Turnover2 006935Net operating expenses:Payroll costs-3 334-3 814Operating expenses:Manufacturing, sub-contracting-980-1 816Travel and subsistence expenses-532-829Leasing and maintenance-431-460Other operating expenses-1 334-1 510Depreciation-511-54Amortization-744 -781 Total net operating expenses- 7 866- 9 264Operating loss-5 860-8 329Net financial loss-1 563-1 859Corporation tax--Net loss-7 423 -10 188 Turno

Wolters Kluwer Annual General Meeting of Shareholders adopts all resolutions22.4.2021 17:25:00 CEST | Press release

Wolters Kluwer Annual General Meeting of Shareholdersadopts all resolutions April 22, 2021 –Wolters Kluwer, a global provider of professional information, software solutions, and services,is pleased to announce that all resolutions were adopted as proposed at today’s Annual General Meeting. Reappointment of members of the Supervisory Board and member of the Executive Board Frans Cremers and Ann Ziegler were reappointed as members of the Supervisory Board and Kevin Entricken was reappointed as member of the Executive Board. The Supervisory Board members represent a diversity of nationality, experience, talent, and expertise. Three (43%) of the seven Supervisory Board members are female, in line with Dutch corporate governance standards and proposed legislation. 2020 Financial Statements and dividend Shareholders voted to adopt the Financial Statements for 2020 as included in the 2020 Annual Report and approved a total dividend of €1.36 per ordinary share, resulting in a final dividend o

Transfer of Huhtamäki Oyj's own treasury shares22.4.2021 16:50:00 CEST | Press release

HUHTAMÄKI OYJ STOCK EXCHANGE RELEASE 22.4.2021 AT 17:50 Transfer of Huhtamäki Oyj's own treasury shares A total of 15,000 of Huhtamäki Oyj's own treasury shares have today been transferred without consideration to the Company's President and CEO Charles Héaulmé as part of his remuneration. The directed issue is based on the authorization given by the Company's Annual General Meeting of 2021 and the decision by the Company's Board of Directors based on the authorization. After the transfer, Huhtamäki Oyj holds a total of 3,395,709 own treasury shares (3.15% of all shares). For further information, please contact: Mr. Sami Pauni, Executive Vice President, Corporate Affairs and Legal, Group General Counsel, tel. +358 (0)10 686 7872 HUHTAMÄKI OYJ Global Communications About Huhtamaki Huhtamaki is a key global provider of sustainable packaging solutions for consumers around the world, enabling wellbeing and convenience. Our innovative products protect on-the-go and on-the-shelf food and bev